Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for quarter and half year ended 30th September, 2026

16th October, 2026 BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Sub: Intimation as per Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’) Board Meeting on Tuesday, 27th October, 2026 Dear Sir / Madam, Pursuant to Regulation 29 of the SEBI Listing Regulations, we write to inform you that a meeting of the Board of Directors of the Company will be held on Tuesday, 27th October, 2026, inter alia to consider and approve the Unaudited Financial Results (Standalone and Consolidated) of the Company for quarter and half year ended 30th September, 2026. In this regard, we also write to inform you that the ‘Trading Window’ for dealing in the securities of the Company, which has been closed from Thursday, 1st October, 2026 will remain closed till Thursday, 29th October, 2026 (both days inclusive). Thanking you, Yours truly, For Piramal Pharma Limited Maneesh Sharma Company Secretary & Compliance Officer Piramal Pharma Limited CIN: L24297MH2020PLC338592 Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070, Maharashtra, India Tel No. +91 22 3802 3000 / 4000; Email Id: shareholders.ppl@piramal.com www.piramalpharma.com